C12N 2501/2323
Interleukin-23
Official title: Interleukin-23 (IL-23)
C12N2501/2323 (Interleukin-23) appears on 12 US grants and 38 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 38
- Assignees
- 31
- Inventors
- 79
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 1 |
| 2015 | 1 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 0 | 3 |
| 2020 | 1 | 6 |
| 2021 | 1 | 3 |
| 2022 | 0 | 0 |
| 2023 | 3 | 6 |
| 2024 | 2 | 8 |
| 2025 | 1 | 1 |
| 2026 | 1 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Method for producing induced pluripotent stem cells20 Jan 2026US 12,529,035 B1National University Corporation Kobe University
- IL-23R antagonists to reprogram intratumoral T regulatory cells into effector cells21 Jan 2025US 12,202,904 B2Dana-Farber Cancer Institute, Inc.
- Ex vivo model of inflamed human skin and uses thereof for screening anti-inflammatory compounds27 Aug 2024US 12,071,648 B2Genoskin
- CD38-NAD+ regulated metabolic axis in anti-tumor immunotherapy30 Jan 2024US 11,883,430 B2MUSC Foundation for Research Development
- Human innate lymphoid cell precursors: identification, characterization, applications20 Jun 2023US 11,680,245 B2Institut National De La Sante Et De La Recherche Medicale (Inserm)
- Innate lymphoid cells for cell therapy and biomarkers therefor18 Jun 2026US 2026/0166081 A9University Health Network
- Treatment of autoimmune diseases having a pathogenic t cell state23 Apr 2026US 2026/0108606 A1The Brigham and Women S Hospital, Inc.
- Methods of making chimeric antigen receptor-expressing cells26 Feb 2026US 2026/0055157 A1Novartis AG
- ALDH Inhibitors to Promote Immune Cell Expansion8 Jan 2026US 2026/0007745 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Innate lymphoid cells for cell therapy and biomarkers therefor11 Dec 2025US 2025/0375479 A1University Health Network
Most cited
By later US patents
- ICOS critically regulates the expansion and function of inflammatory human Th17 cells15US 9,133,436 B2The Trustees of the University of Pennsylvania · 2015
- T cell balance gene expression, compositions of matters and methods of use thereof3US 10,822,587 B2Massachusetts Institute of Technology · 2020
- Cd4+ Cd25+ T-cells activated to a specific antigen1US 8,785,140 B2New South Innovations Pty Limited · 2014
- ICOS critically regulates the expansion and function of inflammatory human Th17 cells1US 9,994,818 B2The Trustees of the University of Pennsylvania · 2018